Phase II evaluation of piroxantrone in renal cell carcinoma
暂无分享，去创建一个
[1] C. Loprinzi,et al. Phase I and clinical pharmacological evaluation of pirozantrone hydrochloride (oxantrazole). , 1990, Cancer research.
[2] L. Grochow,et al. Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole. , 1990, Cancer research.
[3] R. Donehower,et al. Local toxicity of piroxantrone: an anthrapyrazole with irritant and vesicant properties similar to those of doxorubicin. , 1989, Journal of the National Cancer Institute.
[4] W. Leopold,et al. Anthrapyrazoles, a new class of intercalating agents with high-level, broad spectrum activity against murine tumors. , 1985, Cancer research.
[5] D. W. Fry,et al. In vitro DNA strand scission and inhibition of nucleic acid synthesis in L1210 leukemia cells by a new class of DNA complexers, the anthra[1,9-cd]pyrazol-6(2H)-ones (anthrapyrazoles). , 1985, Biochemical pharmacology.
[6] K. Hamelehle,et al. Establishment of adriamycin-resistant mammary adenocarcinoma 16/C in vitro and its sensitivity to the anthrapyrazoles CI-942 and CI-937 , 1985 .